Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GLP1R | P43220 | 5/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18748045 | 0.95 | MEN1 (0.41) | ALDH1A1MEN1KMT2AEPHX2TSHR | |
| SCHEMBL25516086 | 0.91 | MEN1 (0.46) | ALDH1A1MEN1KMT2AEPHX2TSHR | |
| SCHEMBL24040332 | 0.91 | MEN1 (0.41) | MEN1KMT2ATSHRCA2GLP1R | |
| SCHEMBL21172352 | 0.90 | MEN1 (0.40) | MEN1KMT2ATSHRCA2GLP1R | |
| SCHEMBL25455878 | 0.90 | MEN1 (0.40) | MEN1KMT2AEPHX2TSHRCA2 | |
| SCHEMBL23518687 | 0.88 | MEN1 (0.46) | ALDH1A1MEN1KMT2AEPHX2TSHR | |
| SCHEMBL20017289 | 0.88 | MEN1 (0.41) | MEN1KMT2ATSHRCA2GLP1R | |
| SCHEMBL21297376 | 0.87 | GLP1R (0.46) | TSHRGLP1RRECQL | |
| SCHEMBL8214500 | 0.87 | GLP1R (0.46) | TSHRGLP1RRECQL | |
| SCHEMBL21011153 | 0.87 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2AEPHX2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730817-B2 | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction | INVIVOGEN (FR) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730817-B2 | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction | STING1, CGAS, TLR9 | ALDH1A1 4585/4885MEN1 1547/4885KMT2A 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.